N,N'-bis(3-aminopropyl)piperazine

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Type of information:

experimental study

Adequacy of study:

other information

Study period:

February 1979 - January 1980

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

study well documented, meets generally accepted scientific principles, acceptable for assessment

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1980

Report date:

1980

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

other: BASF Test

GLP compliance:

no

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

N,N'-bis(3-aminopropyl)piperazine

EC Number:

230-589-1

EC Name:

N,N'-bis(3-aminopropyl)piperazine

Cas Number:

7209-38-3

Molecular formula:

C10H24N4

IUPAC Name:

3-[4-(3-aminopropyl)piperazin-1-yl]propan-1-amine

Test material form:

liquid

Details on test material:

- name (as stated in the report): N,N'-Bis-aminopropyl-piperazin
- chemical name: 1,4-Bis-(aminopropyl)-piperazin

Test animals

Species:

mouse

Strain:

NMRI

Sex:

male/female

Details on test animals or test system and environmental conditions:

- Diet: Herilan MRH-Haltung, Eggersmann KG
- Weight at study initiation: males: 20 - 30 g, females: 20 - 26 g

Administration / exposure

Route of administration:

intraperitoneal

Vehicle:

water

Doses:

50 (0.5 % dilution), 200 (2.0 %), 700 (7.0 %) mg/kg/bw

No. of animals per sex per dose:

5 animals per sex per dose

Control animals:

no

Details on study design:

The test compound was administered intraperitoneal to 3 groups of 10 mice (5 male, 5 female) fasted for 15 - 20 hours prior to dosing. The animals were observed for 14 days. Decents during the study were examined for gross lession.

Results and discussion

Effect levels

Key result

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 200 - < 700 mg/kg bw

Based on:

test mat.

Mortality:

50 mg/kg bw: 0/5 (females) and 0/5 (males)
200 mg/kg bw: 0/5 (females) and 1/5 (males), The decedent was found at day 7 post-treatment.
700 mg/kg bw: 5/5 (females) and 5/5 (males), The male decedents were found within 1 day post-treatment. 4 female decedents were found within 1 day post-treatment, the other one within 1 hour.

Clinical signs:

50 mg/kg bw: dyspnea, shaggy fur
200 mg/kg bw: dyspnea, apathy, uncoordinated movements, spastic gait, shaggy fur, bad general condition
700 mg/kg bw: dyspnea, apathy, hunched posture, uncoordinated movements, disrupted nociceptive reflex, coma, shaggy fur, exsiccosis, bad general condition

Body weight:

All animals were considered to have achieved satisfactory bodyweight gains throughout the study.

Gross pathology:

dead rats: no intra-abdominal substance precipitation or adhesion

killed rats: thickening of liver edge

Applicant's summary and conclusion

Conclusions:

LD50 (intraperitoneal): >200 < 700 mg/kg/bw

Executive summary:

N,N'-bis-(3 -aminopropyl)piperazine was administered intraperitoneal to 3 groups of 10 mice (5 female, 5 male). The animals were observed for 14 days.

The substance was delivered as formulation in water in 3 different concentrations 7.0 % (700 mg/kg bw), 2.0 % (200 mg/kg bw), 0.5 % (50 mg/kg bw). All animals were subjected to daily observations and weekly determination of body weight. Macroscopic examination was performed on the day of death or after terminal sacrifice (Day 14).

The body weight gain shown by the surviving animals over the study period was considered to be normal.

The LD50 was determined to be >200 < 700 mg/kg/bw.